Biotech: Page 80
-
Startup EQRx to take drug price mission public through $1.8B SPAC deal
A merger with a blank-check company backed by Casdin Capital will greatly expand the resources available to EQRx, which aims to develop competitors to existing drugs and sell them at "radically lower" prices.
By Ned Pagliarulo • Aug. 6, 2021 -
Jacob Bell/BioPharma Dive
Gilead's Kite bets on early-stage biotech to advance allogeneic cell therapies
Appia Bio, which launched with over $50 million in Series A funding earlier this year, will provide preclinical research for two CAR-iNKT candidates, which Kite will pick up should they advance past early clinical testing.
By Shoshana Dubnow • Aug. 5, 2021 -
Explore the Trendline➔
Spencer Platt via Getty Images
TrendlineEmerging biotech
New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.
By BioPharma Dive staff -
Regeneron drug extends survival in lung cancer trial, lifting company's hopes in field
The biotech also reported second quarter earnings on Thursday that widely surpassed Wall Street expectations.
By Jonathan Gardner • Aug. 5, 2021 -
Photo illustration by Maura Sadovi/BioPharma Dive; photograph by Carl Court via Getty Images
Moderna says vaccine protective through six months, but warns boosters needed this fall
Final results from the Phase 3 trial that led to the shot's authorization showed efficacy remained high, at 93%, although that data was collected before the delta variant had spread widely.
By Ned Pagliarulo • Aug. 5, 2021 -
How Bayer lured a biotech away from an IPO and into a buyout
Vividion Therapeutics was headed toward an IPO earlier this year, but the company's co-founder said Bayer’s $1.5 billion offer ended up being a more attractive option.
By Shoshana Dubnow • Aug. 5, 2021 -
Permission granted by Biogen
After controversial approval, doctors are still debating how to use Biogen's Alzheimer's drug
Nearly two months since Aduhelm became available, many physicians have yet to use the first treatment approved in the U.S. to slow Alzheimer's disease.
By Jacob Bell • Updated Aug. 3, 2021 -
Sarah Silbiger via Getty Images
FDA rejects a biotech's kidney drug, but some analysts still see a 'sliver of hope'
The agency wants Ardelyx to run another trial to show its drug affects clinical outcomes for patients with chronic kidney disease. Analysts think this could be accomplished, but would take some time.
By Jacob Bell • July 30, 2021 -
A startup raises $117M to deliver gene therapies in a new way
Flagship Pioneering, the biotech incubator that created Moderna, is helping fund Ring Therapeutics, a startup hoping to disrupt gene therapy development through the use of a different viral vector.
By Kristin Jensen • July 28, 2021 -
Amgen pays $900M for Teneobio and bets bigger on next-gen antibody drugs
The acquisition is the third Amgen has made since March and broadens its ability to develop bispecific antibodies, a drug class of intense interest to big biotech.
By Ben Fidler • July 28, 2021 -
Elizabeth Regan/BioPharma Dive
An AstraZeneca spinout scores a buyout option from Arena
The potential acquisition marks a fast turnaround for Aristea, one of several biotechs formed from programs AstraZeneca decided not to advance internally.
By Jonathan Gardner • July 27, 2021 -
Justin Sullivan via Getty Images
Regeneron, AstraZeneca team up on targeted drugs for obesity
After screening 650,000 people, Regeneron unearthed a mutation associated with lower weight. AstraZeneca aims to help the biotech make a drug based on its findings.
By Jonathan Gardner • July 27, 2021 -
Sean Gallup via Getty Images
BioNTech, WHO hatch plan to bring mRNA vaccines to Africa
Responding to criticism, the German biotech plans to develop a malaria shot and build manufacturing infrastructure on the continent.
By Jonathan Gardner • July 26, 2021 -
del Aguila III, Ernesto. (2018). "CRISPR Cas9" [Illustration]. Retrieved from Flickr.
Caribou raises $304M in one of gene editing's most lucrative IPOs
The IPO is several times larger than what CRISPR Therapeutics, Intellia and Editas raised several years ago, and ranks well ahead of a more recent offering from gene editing startup Beam.
By Ned Pagliarulo • July 23, 2021 -
Seres, after earlier success, fails a key test for microbiome drugs
A pill made of gut bacteria wasn't effective at treating ulcerative colitis in a closely watched study that was viewed as a proof point for the emerging field.
By Ben Fidler • July 22, 2021 -
Permission granted by Biogen
Biogen executives attack Aduhelm criticism, blaming 'extensive misinformation'
The company responded forcefully to controversy roiling around the Alzheimer's drug's approval, defending its data and interactions with the FDA.
By Jonathan Gardner , Ned Pagliarulo • July 22, 2021 -
Amylyx, faced with longer FDA path for promising ALS drug, gets major cash infusion
A $135 million investment will help the small biotech potentially prepare to launch the treatment in Canada and Europe as well as fund another trial requested by U.S. regulators.
By Ned Pagliarulo • Updated July 20, 2021 -
BioNTech returns to cancer roots with deal for Gilead cell therapy factory
The German biotech purchased Kite Pharma's Gaithersburg, Maryland-based site, along with related research on T cell receptor-based cancer treatments.
By Shoshana Dubnow • July 19, 2021 -
Elizabeth Regan/BioPharma Dive
Cytokinetics heart drug succeeds in mid-stage study, boosting shares
Treatment with one of the biotech's drugs improved heart function in a small trial, an outcome that could help the company rebound and potentially challenge a rival medicine from Bristol Myers Squibb.
By Ned Pagliarulo • July 19, 2021 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
COVID-19 drug developer Adagio plans IPO to cap fast rise
The offering is the latest step in the rapid emergence of Adagio, which raised $465 million and brought a drug to pivotal testing in less than a year.
By Ben Fidler • July 19, 2021 -
FDA advisers push back on FibroGen anemia drug
Safety worries led to a near-unanimous vote against roxadustat in kidney disease patients, dimming the approval chances of what would be the first pill to boost red blood cells.
By Jonathan Gardner • July 16, 2021 -
Permission granted by Biogen
Major health centers, insurers push back against Aduhelm
The Cleveland Clinic and Mount Sinai won't yet administer the controversial Alzheimer's drug, while UnitedHealth's CEO said the insurer would need more time to iron out coverage.
By Jacob Bell • July 15, 2021 -
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
A cancer drug startup banks new funds for NK cell therapy
Backed by Abingworth, Tybourne Capital and others, Wugen has raised $172 million in a Series B round meant to fuel research of its leukemia treatment.
By Kristin Jensen • July 15, 2021 -
Courtesy of Galapagos
Galapagos shares sink as first data from touted drug program disappoints
The biotech will push forward with other candidates from its "Toledo" research, but investors did not appear encouraged by the mixed data Wednesday.
By Ned Pagliarulo • Updated July 20, 2021 -
Permission granted by Prime Medicine
Prime Medicine raises $315M to fuel 'search-and-replace' gene editing work
Formed around research from the Broad Institute's David Liu and Andrew Anzalone, Prime has attracted significant funding from a wide range of high-profile biotech backers.
By Shoshana Dubnow • July 14, 2021 -
Permission granted by Biohaven Pharmaceutical
Q&ABiohaven CEO on migraine drug's fast launch, TikTok ads and battling big pharma
Sales of Nurtec ODT during the second quarter were double what Wall Street expected. CEO Vlad Coric explained to BioPharma Dive how the biotech did it, despite being far smaller than its chief rival.
By Jacob Bell • July 14, 2021
Previous
